{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:09:44Z","timestamp":1760954984104},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s11936-005-0029-8","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T09:42:09Z","timestamp":1180863729000},"page":"443-448","source":"Crossref","is-referenced-by-count":12,"title":["Current therapeutic strategies in cardiac amyloidosis"],"prefix":"10.1007","volume":"7","author":[{"given":"Shailja","family":"Parikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A. de","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"29_CR1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/01.CIR.91.4.1269","volume":"91","author":"R Kyle","year":"1995","unstructured":"Kyle R: Amyloidosis. Circulation 1995, 91:1269\u20131270.","journal-title":"Circulation"},{"key":"29_CR2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0002-9149(99)00832-2","volume":"85","author":"M Grogan","year":"2000","unstructured":"Grogan M, Gertz MA, Kyle R, et al.: Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2000, 85:664\u2013665.","journal-title":"Am J Cardiol"},{"key":"29_CR3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:583\u2013596.","journal-title":"N Engl J Med"},{"key":"29_CR4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","volume":"336","author":"D Jacobson","year":"1997","unstructured":"Jacobson D, Pastore R, Yaghoubian R, et al.: Variantsequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997, 336:466\u2013473.","journal-title":"N Engl J Med"},{"key":"29_CR5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0002-9149(77)80125-2","volume":"39","author":"R Swanton","year":"1977","unstructured":"Swanton R, Brooksby I, Davies M, et al.: Systolic and diastolic ventricular function in cardiac amyloidosis: studies in six cases diagnosed with endomyocardial biopsy. Am J Cardiol 1977, 39:658\u2013664.","journal-title":"Am J Cardiol"},{"key":"29_CR6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","volume":"104","author":"R Liao","year":"2001","unstructured":"Liao R, Jain M, Teller P, et al.: Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001, 104:1594\u20131597.","journal-title":"Circulation"},{"key":"29_CR7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0002-9149(75)90891-7","volume":"36","author":"C Chew","year":"1975","unstructured":"Chew C, Mokhtar G, Raphael M: The functional defect in amyloid heart disease: the \u201cstiff heart\u201d syndrome. Am J Cardiol 1975, 36:438\u2013444.","journal-title":"Am J Cardiol"},{"key":"29_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","volume":"49","author":"J Carroll","year":"1982","unstructured":"Carroll J, Gaasch W, McAdam P: Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation. Am J Cardiol 1982, 49:9\u201313.","journal-title":"Am J Cardiol"},{"key":"29_CR9","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","volume":"107","author":"G Palladini","year":"2003","unstructured":"Palladini G, Campana C, Klersy C, et al.: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker for myocardial dysfunction in AL amyloidosis. Circulation 2003, 107:2440\u20132445.","journal-title":"Circulation"},{"key":"29_CR10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2003.08.043","volume":"43","author":"J Rahman","year":"2004","unstructured":"Rahman J, Helou E, Gelzer-Bell R, et al.: Noninvasive diagnosis of biopsy proven cardiac amyloidosis. J Am Coll Cardiol 2004, 43:410\u2013415.","journal-title":"J Am Coll Cardiol"},{"key":"29_CR11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0002-8703(98)70127-9","volume":"136","author":"R Fatorri","year":"1998","unstructured":"Fatorri R, Rocchi G, Cellati F, et al.: Contribution of magnetic resonance imaging in identification of amyloid cardiomyopathy. Am Heart J 1998, 136:824\u2013830.","journal-title":"Am Heart J"},{"key":"29_CR12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/01.CIR.0000153623.02240.20","volume":"111","author":"R Kwong","year":"2005","unstructured":"Kwong R, Falk R: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005, 111:122\u2013124.","journal-title":"Circulation"},{"key":"29_CR13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","volume":"63","author":"A Rubinow","year":"1981","unstructured":"Rubinow A, Skinner M, Cohen A: Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981, 63:1285\u20131288.","journal-title":"Circulation"},{"key":"29_CR14","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/0002-9149(85)90996-8","volume":"55","author":"M Gertz","year":"1985","unstructured":"Gertz M, Skinner M, Connors L: Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985, 55:1646.","journal-title":"Am J Cardiol"},{"key":"29_CR15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","volume":"97","author":"E Choufani","year":"2001","unstructured":"Choufani E, Sanchorawala V, Ernst T, et al.: Acquired factor X deficiency in patients with amyloid lightchain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001, 97:1885\u20131887.","journal-title":"Blood"},{"key":"29_CR16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"R Kyle","year":"1997","unstructured":"Kyle R, Gertz M, Greipp P, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336:1202\u20131207.","journal-title":"N Engl J Med"},{"key":"29_CR17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.1999.17.1.262","volume":"17","author":"M Gertz","year":"1999","unstructured":"Gertz M, Lacy M, Just J, et al.: Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999, 17:262\u2013267.","journal-title":"J Clin Oncol"},{"key":"29_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, Sanchorawala V, Seldin D, et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85\u201393.","journal-title":"Ann Intern Med"},{"key":"29_CR19","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","volume":"91","author":"R Comenzo","year":"1998","unstructured":"Comenzo R, Vosburgh E, Falk R: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662\u20133670.","journal-title":"Blood"},{"key":"29_CR20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V86.3.855.855","volume":"86","author":"L Gianni","year":"1995","unstructured":"Gianni L, Bellotti V, Gianni M, et al.: New drug therapy of amyloidosis: resorption of AL-type deposits with 4\u2032-iodo-4\u2032-deoxydoxorubicin. Blood 1995, 86:855\u2013861.","journal-title":"Blood"},{"key":"29_CR21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V93.3.1112","volume":"93","author":"G Merlini","year":"1999","unstructured":"Merlini G, Anesi E, Garini P, et al.: Treatment of AL amyloidosis with 4\u2032-iodo-4\u2032-deoxydoxorubicin: an update. Blood 1999, 93:1112\u20131113.","journal-title":"Blood"},{"key":"29_CR22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/heart.85.2.202","volume":"85","author":"S Dubrey","year":"2001","unstructured":"Dubrey S, Burke M, Khaghani A, et al.: Long-term results of heart transplantation in patients with amyloid heart disease. Heart 2001, 85:202\u2013207. Reviews the results of 13 years of follow-up of patients with cardiac amyloidosis undergoing heart transplantation.","journal-title":"Heart"},{"key":"29_CR23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7326\/0003-4819-82-4-466","volume":"82","author":"H Cohen","year":"1975","unstructured":"Cohen H, Lessin L, Kyle R, et al.: Resolution of primary amyloidosis during chemotherapy: studies in patients with nephrotic syndrome. Ann Intern Med 1975, 82:466\u2013473.","journal-title":"Ann Intern Med"},{"key":"29_CR24","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","volume":"92","author":"G Merlini","year":"1995","unstructured":"Merlini G, Ascari E, Amboldi N, et al.: Interaction of the anthracycline 4\u2032-iodo-4\u2032-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995, 92:2959\u20132963.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-005-0029-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0029-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T17:38:09Z","timestamp":1587577089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-005-0029-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s11936-005-0029-8","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}